US Patent Issued to Aragon Pharmaceuticals on May 20 for "Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer" (California Inventor)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,303,497, issued on May 20, was assigned to Aragon Pharmaceuticals Inc. (Los Angeles).

"Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer" was invented by Margaret K. Yu (Los Angeles).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide."

The patent was filed on Oct. 31, 2023, under Application No. 18/498,542.

*For further information, including images, charts and tables, pl...